Scientists have developed an experimental drug that in one dose successfully protected nonhuman primates against a lethal infection of all strains of the deadly Ebola virus. Thomas Geisbert from The University of Texas Medical Branch in the US said that previous therapeutics typically were of the “one bug, one drug” variety. However, because of the unpredictable nature and variety of the Ebola virus, scientists have been seeking a way to protect against different strains of the virus. 
 
What
  1. The study, published in the journal Cell Host & Microbe, found that a two-antibody cocktail called MBP134 could fully protect nonhuman primates and ferrets against lethal Ebola virus infections caused by the Bundibugyo and Sudan strain as well as the deadliest Zaire strain that caused the 2013-16 epidemic in West Africa and the current outbreak in the Democratic Republic of Congo.
  2. Further studies exploring even lower doses could open the door to treatment via auto-injectors like the kind used for allergic reactions. 
  3. The ability to quickly and efficiently provide protection against all Ebola viruses in a single dose would reduce the burden on health care workers in the field during outbreaks, especially in regions that have a less-developed infrastructure.
What is Ebola?
  1. Ebola is a deadly disease caused by a virus. There are five strains, and four of them can make people sick
  2. After entering the body, it kills cells, making some of them explode. It wrecks the immune system, causes heavy bleeding inside the body, and damages almost every organ.
  3. The virus is scary, but it’s also rare. You can get it only from direct contact with an infected person’s body fluids.
  4. Ebola virus disease (EVD) first appeared in 1976 in 2 simultaneous outbreaks, one in what is now, Nzara, South Sudan, and the other in Yambuku, Democratic Republic of Congo. 
  5. The latter occurred in a village near the Ebola River, from which the disease takes its name.

#EbolaDrug #ExperimentalDrug #EbolaVirus #Ebola #LethalInfection

Print Friendly, PDF & Email